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ASD, a number of comorbid psychiatric disorders are inde-
pendent predictors for antipsychotic treatment, even after 
adjustment for familial, socio-demographic and individual 
factors. As current trial evidence excludes children with 
comorbidity, more pragmatic randomised controlled trials 
with long-term drug monitoring are needed.
Keywords Child and adolescence · Autism spectrum 
disorders · Antipsychotic medications · Psychiatric 
comorbidity · Challenging behaviours
Introduction
Antipsychotics are the most common psychotropic medica-
tion prescribed to children with autism spectrum disorders 
(ASD) [1]. US-based studies suggest between 20 and 34 % 
of children with ASD receive antipsychotics [2, 3]. Rates 
are lower in Europe, between 7 and 11 % [4, 5], but appear 
to be increasing [6]. Two atypical antipsychotics in particu-
lar are most commonly used, risperidone and aripiprazole, 
which have been demonstrated to be effective in reducing 
“irritability” in children with ASD, but show limited impact 
on the core features of ASD [7].
Clinicians and families face a difficult task when decid-
ing whether antipsychotic treatment is indicated. Evidence 
from antipsychotic trials in childhood ASD is derived from 
samples that bear little resemblance to children typically 
seen in clinical practice, as they exclude children with 
formally diagnosed psychiatric comorbidity [8]. Another 
problem is the almost exclusive focus of trials on irrita-
bility as a target symptom in ASD. Irritability is a highly 
prevalent symptom in clinical settings, it has no standard 
taxonomy, and is associated with most childhood mental 
health problems [9]. Therefore, based on trial evidence, 
Abstract Children with autism spectrum disorders 
(ASD) are more likely to receive antipsychotics than any 
other psychopharmacological medication, yet the psy-
chiatric disorders and symptoms associated with treat-
ment are unclear. We aimed to determine the predictors 
of antipsychotic use in children with ASD receiving psy-
chiatric care. The sample consisted of 3482 children aged 
3–17 with an ICD-10 diagnosis of ASD referred to mental 
health services between 2008 and 2013. Antipsychotic use 
outcome, comorbid diagnoses, and other clinical covari-
ates, including challenging behaviours were extracted from 
anonymised patient records. Of the 3482 children (79 % 
male) with ASD, 348 (10 %) received antipsychotic medi-
cation. The fully adjusted model indicated that comorbid 
diagnoses including hyperkinetic (OR 1.44, 95 %CI 1.01–
2.06), psychotic (5.71, 3.3–10.6), depressive (2.36, 1.37–
4.09), obsessive–compulsive (2.31, 1.16–4.61) and tic dis-
orders (2.76, 1.09–6.95) were associated with antipsychotic 
use. In addition, clinician-rated levels of aggression, self-
injurious behaviours, reduced adaptive function, and over-
all parental concern for their child’s presenting symptoms 
were significant risk factors for later antipsychotic use. In 
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the type and severity of childhood ASD-related irritabil-
ity symptoms, which warrant antipsychotic treatment, are 
unclear. Furthermore, antipsychotic medication does not 
have UK marketing authorisation for use in childhood 
ASD, although risperidone is licensed for use in the short-
term management of aggression in children with conduct 
disorder [10]. Balancing antipsychotic risk-benefit profiles 
is further complicated by little safety evidence being avail-
able for children with ASD [11, 12]. Antipsychotic use for 
children in general is associated with a number of adverse 
health outcomes, most commonly extrapyramidal side 
effects, obesity and hyperprolactinaemia [13]. Given the 
limited evidence base, NICE guidelines advocate cautious 
antipsychotic prescribing in children with ASD and only to 
treat severe challenging behaviours (also known as ‘behav-
iours that challenge’) such as aggression, self-injury and 
impulsive/dangerous behaviours [14].
It remains unclear how current evidence, licensing and 
guidance for antipsychotic use in children with ASD are 
applied clinically [15]. There are very few UK-based natu-
ralistic studies of prescribing in children with ASD, and, as 
yet, no examinations of the diagnostic predictors of antipsy-
chotic use [4]. Comorbid psychiatric disorders are common 
(and frequently multiple) in children with autism spectrum 
disorders and may be targets for intervention [16]. Current 
knowledge is largely based on parent reports in US surveys 
which indicate that antipsychotics are used predominantly 
to treat comorbid diagnoses (e.g. depression, bipolar, anxi-
ety, conduct disorder and attention deficit hyperactivity dis-
orders) in children with ASD [2, 3]. However, these find-
ings may not generalise to non-US clinical populations as 
US antipsychotic marketing [17], prescribing policy [18, 
19] and practice differ markedly to the other Western Coun-
tries [1, 20]. Given that the majority of the aforementioned 
studies report cross-sectional findings from retrospective 
parental accounts of both comorbidity and past medication 
use, the direction of effect is unclear, and recall bias may 
obscure true prescribing patterns. Furthermore, these stud-
ies do not account for important confounding factors, such 
as psychosis, adaptive function, and intellectual disability 
that may lead to an overestimate of the association between 
certain comorbidities and antipsychotic use.
To clarify how antipsychotics are used in childhood 
ASD, we explored the clinical factors that predicted antip-
sychotic prescribing. We conducted a historical cohort 
study using the anonymised electronic health records of 
children with ASD treated by UK child and adolescent 
mental health services (CAMHS). As challenging behav-
iours (or ‘behaviours that challenge’) are symptoms that 
cut across most childhood psychopathology, we hypoth-
esised that the common psychopathologies are comorbid 
with ASD including hyperkinetic, oppositional and con-
duct, depression and anxiety disorders would all show 
longitudinal associations with antipsychotic use. We also 
examined whether associations between comorbidity and 
antipsychotics were attenuated after we controlled for chal-
lenging behaviours, given that these are the most common 
non-psychotic symptoms formally recognised as targets for 
antipsychotic treatment by current national ASD manage-
ment guidelines [14].
Methods
Study setting
This study used data extracted from the anonymised, elec-
tronic clinical records of children referred to South London 
and Maudsley NHS Foundation Trust (SLaM) between 
1 January 2008 and 31 December 2013. Over this period, 
SLaM provided all aspects of specialist mental health-
care to a catchment population of approximately 300,000 
children resident within four London boroughs (Lambeth, 
Southwark, Lewisham, Croydon). In addition to the dis-
trict services, SLaM provided specialist inpatient and out-
patient ASD assessment and treatment services for young 
people from across the UK. Each borough had a dedicated 
multidisciplinary service for children, which accepted 
referrals for school age children (4–18 years; exception-
ally cases are accepted below this age) with suspected or 
previously confirmed ASD, displaying emotional or behav-
ioural difficulties. Children were referred from primary 
care, child health, and educational and social care services, 
and typically underwent a multidisciplinary assessment 
by CAMHS clinicians. Primary and secondary psychiat-
ric disorders were diagnosed by CAMHS using the ICD-
10 multi-axial classification system [21]. Semi-structured 
validated assessments, for example, the Autism Diagnostic 
Observation Schedule (ADOS) [22] were used if an ASD 
diagnosis was unclear after initial assessment (the SLaM 
autism pathway is available from the author on request). 
Compared with expert consensus, there is a high specificity 
for ASD diagnoses by clinicians working at a district level 
[23]. Socio-demographic characteristics and clinical infor-
mation were recorded using computerised assessment pro-
forma, which included the Strengths and Difficulties Ques-
tionnaire (SDQ) [24].
The Clinical Record Interactive Search (CRIS) system 
was used to provide an anonymised, electronic mental 
health records database to search on structured data and 
free text fields on over 34,400 child and adolescent cases 
referred to SLaM services. Generalised Architecture for 
Text Engineering (GATE), a natural language processing 
architecture was applied to extract data from the free text 
(progress notes, correspondence, etc.) and structured fields 
[25].
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Study sample
Cases were part of an open clinical cohort (entering and 
leaving the study at different time points) and included 
children aged 3–17 years with a diagnosis of ASD (Inter-
national Classification of Diseases, 10th Revision (ICD-
10) F84.0, F84.1, F84.5, F84.9) [21] recorded between 
1 January 2008 and 31 December 2013. Children were 
excluded if any past course of antipsychotic treatment was 
noted in the clinical record in the year prior to the observa-
tion period.
Measurements
Outcome: antipsychotic use
Antipsychotic use outcome data were extracted from free 
text fields held in the SLaM Case Register, the SLaM 
pharmacy dispensing database and structured medica-
tion fields in the electronic health record using vali-
dated GATE software extraction methods [26]. Antipsy-
chotic use was measured during the observation period 
(01/01/2008–31/12/2013). The start date for antipsychotic 
use was recorded and categorised as a present/absent 
outcome.
Exposure: psychiatric comorbidity and intellectual 
disability
The main exposure was ICD-10 recorded comorbid 
psychiatric diagnoses, which were extracted from free 
text and structured fields. ICD-10 Axis one comorbid 
diagnoses were categorised into: psychotic (F1x.5, F20–
F29, F31, F32.3, F33.3), depressive disorders (F32), 
anxiety, stress and emotional (F40–41, F43–F48, F93), 
obsessive–compulsive (F42), hyperkinetic (F90), oppo-
sitional defiant and conduct (F91–F92) and tic (F95). 
Low frequency psychiatric diagnoses were collapsed 
into a single category labelled “Other”. In addition, 
children were categorised according to presence of an 
ICD-10 Axis three diagnosis of intellectual disability 
(F70–F79).
Prescribing decisions were recorded contemporaneously, 
but there was often a short administrative lag before diag-
nostic reports appeared in the electronic medical record. 
These reports contained detailed clinical assessments con-
ducted during the pre-medicated period. To permit inclu-
sion of these longitudinally collected clinical data, but also 
ensure comorbidity exposures occurred prior to antipsy-
chotic use, comorbid diagnoses were only coded as present 
if they were recorded before, or up to 30 days after, record-
ing of antipsychotic medication.
Covariates
All covariates were extracted from the medical record dur-
ing the initial CAMHS assessment period, and prior to 
antipsychotic use. Measures of challenging behaviours 
were taken from the SLaM risk assessment proforma. We 
chose assessment items with high face validity for chal-
lenging behaviours, as described by expert consensus in 
national guidance [14], including physical aggression 
against self (self-injury), violence and aggression to oth-
ers or property (aggression), harm through loss of self 
care such as not drinking or eating (self-neglect), impul-
sive and dangerous acts (high-risk behaviours), and habit-
ual behaviours related to intellectual disability such as 
rocking or skin picking that can cause injury (ID-related 
harm). Clinicians rated severity along a 4-point categori-
cal scale: ‘None’, ‘Low’, ‘Moderate’, or ‘High’ (avail-
able on request). For ease of clinical interpretation and to 
ensure adequate numbers in each category, this scale was 
converted into a binary variable for each behaviour domain 
(Moderate or High rating categorised as High risk = 1; 
None or Low ratings, low risk = 0). Children’s adaptive 
functioning was rated using Children’s Global Assessment 
Scale (CGAS) [27], except for those children with signifi-
cant ID, where the Developmental Disabilities CGAS was 
used in some cases [28]. Higher scores (range 0–100) are 
associated with better functioning.
Demographic and family covariates consisted of gender, 
ethnicity, history of parental mental illness, and clinician-
rated levels of parental concern for their child’s symp-
toms at their initial presentation to CAMHS, which were 
retrieved using CRIS from structured fields in the source 
dataset. Age at CAMHS assessment was calculated at the 
date of the first recorded diagnosis of autism spectrum dis-
order within the clinical record. UK Census data provided 
small area (average 400 households) level deprivation 
scores [29].
Emotional, hyperactive and conduct problem domains 
were assessed via the caregiver versions of the 25-item 
Strengths and Difficulties Questionnaire which has sound 
psychometric properties in clinical samples [30]. These 
were available in the clinical record for a third of the sam-
ple (n = 1234, 35 %).
Analysis
To authenticate clinically recorded common comorbid con-
ditions (depression and anxiety, hyperkinetic and conduct 
disorders), we used a sub-group of the cohort with com-
pleted SDQs (n = 1234). Independent sample t tests were 
used to test for statistical differences in parental reported 
SDQ psychopathology subscale scores (emotional, 
 Eur Child Adolesc Psychiatry
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hyperactivity, conduct problem subscales) for children with 
and without these common comorbid conditions.
Logistic regression was used to examine whether antip-
sychotic use was predicted by demographic characteristics, 
psychiatric comorbidities, intellectual disability, adaptive 
function, behaviours that challenge, parental characteris-
tics and neighbourhood deprivation. Multivariable analysis 
was then conducted to examine the effect of each of these 
variables on antipsychotic use after adjusting all other indi-
vidual and contextual covariates (listed in Table 1). The fol-
lowing sensitivity analyses were carried out: (1) using non-
aggregated challenging behaviour categories (4 levels) as 
the binary variable may have introduced residual confound-
ing; (2) excluding those who came from outside the local 
catchment (these individuals may have had substantial con-
tact with non-SLaM services not represented in the CRIS 
source dataset); (3) selecting those with only one comorbid 
disorder and modelling the effect of a single comorbidity 
on antipsychotic use (without adjusting for the full set of 
covariates). All analyses were conducted using Stata ver-
sion 12.
Results
Over the 6-year observation period, we identified 3482 
children aged below 18 years (2686 male and 796 female) 
with a diagnosis of ASD. The mean (SD) exposure to child 
mental health services, defined as the time between the 
date of recorded ASD diagnosis and the end of the obser-
vation period or date of 18th Birthday (whichever sooner) 
was 968 (597) days. Three hundred and forty-eight children 
were prescribed antipsychotics, mainly risperidone (55 %, 
n = 191) and aripiprazole (32 %, n = 112). All were receiv-
ing adjunctive psycho-social interventions. Table 1 shows 
the characteristics of the total sample and those prescribed 
antipsychotics. Nearly 75 % of children prescribed antipsy-
chotics were in the adolescent age range (age 13–18 years), 
representing a sixfold risk (OR 6.29, 95 % CI 3.40–12.1) 
relative to early childhood (age 3–6 years).
In our authentication analyses, we found that ASD chil-
dren diagnosed with comorbid emotional (depression and 
anxiety), hyperkinetic or conduct disorders had signifi-
cantly higher SDQ subscales scores within their respective 
SDQ domains (emotional, hyperactive, conduct) compared 
with children without the respective comorbid diagnosis 
(see supplementary Table 1). ICD-10 recorded comorbid 
psychiatric diagnoses were present in 54 % of the sample, 
a quarter diagnosed with a hyperkinetic disorder, and 20 % 
diagnosed with intellectual disability. Table 2 provides fur-
ther details of comorbid psychiatric diagnoses by antip-
sychotic use. Antipsychotics were prescribed to approxi-
mately half of children with ASD and psychotic disorder, 
and over a quarter of children diagnosed with obsessive–
compulsive disorder, or tic disorders.
In the adjusted model, positive associations with antip-
sychotic use remained significant for age at the time of 
assessment, clinician-rated aggression, self-injurious 
behaviour, and high parental concern for their child’s 
symptoms at initial presentation (see Table 3). In addition, 
adaptive function and the presence of caregiver substance 
misuse showed strong inverse associations with antipsy-
chotic use. Associations with ethnicity, caregiver mental ill-
ness and neighbourhood deprivation were non-significant. 
Table 4 shows that a number of comorbid ICD-10 mental 
disorders, even after adjustment for all other covariates 
and comorbidities, remained significantly associated with 
antipsychotic use including hyperkinetic (OR 1.44, 95 %CI 
1.01–2.06), psychotic (OR 5.71, 3.3–10.6), depressive 
(2.36, 1.37–4.09), obsessive–compulsive (2.31, 1.16–4.61) 
and tic disorders (2.76, 1.09–6.95). These associations 
remained when antipsychotic use was compared between 
ASD children with no-comorbidity to those who had the 
specific comorbidity alone, rather than multiple comorbidi-
ties (for example, only comorbid hyperkinetic disorder, see 
supplementary Table 2). 
Specified sensitivity analyses that used non-aggregated 
behaviour categories produced little change to the over-
all pattern of results in the fully adjusted models, with the 
direction and magnitude of effect being consistent across 
the comorbidities. Similarly, removing the children resi-
dent outside the local catchment area from the sample 
(n = 1170, 33 %) produced little change, except for oppo-
sitional defiant and conduct disorder, where the sensitivity 
analysis produced very imprecise estimates due to the low 
number of children within the diagnostic category.
Discussion
In the largest study to date using non-administrative, clini-
cal mental health records in ASD, we found antipsychotic 
prescribing for children with ASD was strongly associ-
ated with comorbidity. Intellectual disability and psychi-
atric comorbidities, including hyperkinetic, depression, 
psychotic, obsessive–compulsive and tic disorders, were 
all associated with antipsychotic treatment, even after con-
trolling for clinician-rated challenging behaviour symp-
toms at initial assessment. We also found increasing age, 
aggression, self-injurious behaviour, level of adaptive func-
tion, and parental concern were all significant predictors of 
antipsychotic use.
The observed association between antipsychotic use 
and age is consistent with previous ASD studies [2, 31]. 
Over two-thirds of children treated with antipsychotics 
were adolescents. This highlights the need for more trials 
Eur Child Adolesc Psychiatry 
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Table 1  Individual and contextual characteristics of 3482 children with autism spectrum disorders and antipsychotic use referred to local and 
specialist child and adolescent mental health services
Child age category At CAMHS assessment At antipsychotic use
n (%) Mean (SD) n (%) Mean (SD)
 Early (3–6 years) 362 (10.4 %) 4.9 (0.77) 3 (0.9 %) 5.7 (0.3)
 Mid (6–12 years) 1664 (47.8 %) 9.0 (1.69) 89 (25.6 %) 9.6 (1.4)
 Late (13–17 years) 1456 (41.8 %) 14.8 (1.66) 256 (73.5 %) 15.1 (1.6)
Total sample n = 3482 Sample receiving antipsychotics n = 348
Male 2686 (77.1 %) 249 (71.6 %)
Female 796 (22.9 %) 99 (28.4 %)
Ethnicity
 White British 1683 (48.3 %) 208 (59.8 %)
 White other 170 (4.9 %) 11 (3.2 %)
 East Asian 68 (2.0 %) 9 (2.6 %)
 British/Black African 651 (18.7 %) 57 (16.4 %)
 British/Black Caribbean 130 (3.7 %) 5 (1.4 %)
 Mixed Heritage 386 (11.1 %) 37 (10.6 %)
 South Asian 84 (2.4 %) 11 (3.2 %)
 Not stated 310 (8.9 %) 10 (2.8 %)
Adaptive function
 Children’s Global Assessment Scale (CGAS)a
  0–25 (most impaired) 174 (5.7 %) 50 (15.0 %)
  25–50 1346 (43.8 %) 219 (65.6 %)
  50–75 1465 (47.7 %) 62 (18.5 %)
  75–100 89 (2.90 %) 3 (0.9 %)
 Challenging behaviours self injuryb
  Low 2368 (83.3 %) 171 (57.0 %)
  High 474 (16.7 %) 129 (43.0 %)
 ID-related harmc
  Low 1600 (59.3 %) 142 (48.6 %)
  High 1097 (40.7 %) 150 (51.4 %)
 Aggressiond
  Low 1724 (59.7 %) 100 (32.3 %)
  High 1165 (40.3 %) 210 (67.7 %)
 Self-neglecte
  Low 2562 (89.5 %) 231 (75.0 %)
  High 300 (10.5 %) 77 (25.0 %)
 High-risk behavioursf
  Low 2175 (76.9 %) 161 (53.5 %)
  High 654 (23.1 %) 140 (46.5 %)
Family characteristics
 Caregiver mental illnessg
  No 2309 (77.1 %) 247 (77.2 %)
  Yes 685 (22.9 %) 73 (22.8 %)
 Caregiver substance misuseg
  No 2793 (93.3 %) 304 (95.0 %)
  Yes 201 (6.7 %) 16 (5.0 %)
 Parental concernh
  Low 876 (30.1 %) 33 (10.6 %)
  High 2033 (69.9 %) 278 (89.4 %)
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that include this age group but also suggests that treat-
ment acceptability, and hence trial recruitment, will be 
more feasible than in younger children. Social factors also 
appeared to play a role; clinicians who perceived greater 
parental concern for children’s presenting symptoms were 
more likely to prescribe antipsychotic treatment. We are not 
aware of any prior studies that measure parental influences 
on antipsychotic use in ASD; however, our finding is con-
sistent with previous studies that show a positive associa-
tion between parental strain and medication treatment for 
childhood disruptive disorders [32]. Consistent with several 
other investigations in clinical samples [33, 34], our unad-
justed analyses suggest that there may be discrepancies 
between ethnic groups regarding prescribing antipsychotic 
medication to children. However, in keeping with a more 
recent study on psychotropic treatment in children, we 
found that after adjustment for markers of clinical severity, 
ethnicity was no longer significantly associated with antip-
sychotic use [35].
Using a historical cohort design in a clinical sample of 
children with ASD, this is the first longitudinal study of 
challenging behaviours and psychiatric comorbidity pro-
files as predictors of antipsychotic use. Our results sug-
gest that clinicians are using antipsychotics where they 
are known to be efficacious [7]; to target aggression and 
self-injurious behaviours. Many studies so far have been 
hindered by parental report of comorbidities and medica-
tion use, retrospective or cross-sectional design, or the 
confounding effect of unmeasured psychiatric symptoms 
and disorder severity not being accounted for [2, 3, 36]. In 
addressing these limitations we found that, unlike a number 
of US studies, antipsychotics were not significantly associ-
ated with comorbid anxiety, emotional and stress disorders 
[2, 3, 36].
This study has a number of strengths: we used longitu-
dinally collected clinician recorded data in an unselected 
population of children and adolescents with ASD referred 
to CAMHS to study off-label antipsychotic use. This avoids 
the non-response or recall bias issues that may arise in sur-
veys of parents. Our sample included the entire psychiat-
ric population of four south London boroughs for school 
Table 2  Prevalence of comorbid psychiatric disorder and antipsy-
chotic treatment in 3482 children with autism spectrum disorders
(−) comorbidity absent (+) comorbidity present
**Remaining, rarely occurring diagnoses, were collapsed into a sin-
gle category labelled Other (includes ICD-10 F50 eating disorders, 
F04–09 organic disorders, F1x.1–4 substance misuse, F94.1–2 attach-
ment disorders)
Total sample n = 3482 Sample receiving antipsychotics 
n = 348
Any comorbid disorder
 − 1585 (45.5 %) 63 (18.1 %)
 + 1897 (54.5 %) 285 (81.9 %)
Hyperkinetic
 − 2620 (75.2 %) 227 (65.2 %)
 + 862 (24.8 %) 121 (34.8 %)
Oppositional and conduct
 − 3226 (92.7 %) 297 (85.3 %)
 + 256 (7.3 %) 51 (14.7 %)
Depression
 − 3328 (95.6 %) 312 (89.7 %)
 + 154 (4.4 %) 36 (10.3 %)
Anxiety, emotional and stress
 − 3203 (92.0 %) 303 (87.1 %)
 + 279 (8.0 %) 45 (12.9 %)
Obsessive–compulsive
 − 3385 (97.2 %) 322 (92.5 %)
 + 97 (2.8 %) 26 (7.5 %)
Tic
 − 3431 (98.5 %) 335 (96.3 %)
 + 51 (1.5 %) 13 (3.7 %)
Psychosis
 − 3366 (96.8 %) 294 (84.5 %)
 + 116 (3.3 %) 54 (15.5 %)
Intellectual disability
 − 2826 (81.2 %) 234 (67.2 %)
 + 656 (18.8 %) 114 (32.8 %)
Other**
 − 3353 (96.3 %) 330 (94.8 %)
 + 129 (3.7 %) 18 (5.2 %)
Missing cases = a 408, b640, c785, d593, e 620, f653, g488, h 573, i236
Table 1  continued
Total sample n = 3482 Sample receiving antipsychotics n = 348
Neighbourhood characteristicsi
 Level of deprivation (tertiles)
  1st (least deprived) 1064 (32.8 %) 142 (44.4 %)
  2nd 1093 (33.7 %) 95 (29.7 %)
  3rd (most deprived) 1089 (33.6 %) 83 (25.9 %)
Eur Child Adolesc Psychiatry 
1 3
age children (4–18 years) with suspected or previously 
confirmed ASD and displaying emotional or behavioural 
difficulties, in addition to children from other areas of the 
UK referred to National and Specialist services. However, 
because we studied a cohort enriched by national referrals, 
psychiatric comorbidity and antipsychotic treatment, preva-
lence should not be taken as representative rates of the chil-
dren with ASD in the general population.
Our study has limitations. First, an ASD diagnosis 
may ‘overshadow’ other psychiatric diagnoses and reduce 
the likelihood of clinicians recording additional psychiat-
ric diagnoses. For example, ICD-10 criteria preclude the 
diagnosis of hyperkinetic disorder being given once ASD 
is established, which may lead to an underestimate of the 
association between hyperkinetic comorbidity and antipsy-
chotic use. That said, many clinicians override this instruc-
tion based on recent evidence from clinical and treatment 
studies. Second, the type of assessment and treatments 
offered to families may vary by clinician. In our analysis, 
we lacked detailed information about the assessing and 
prescribing clinician and could not account for variation in 
practice. Third, we did not include physical comorbidities 
(e.g. epilepsy, obesity), other pharmacological treatments 
or duration of psycho-social interventions which may act as 
potential confounders to antipsychotic use. Fourth, we did 
not apply a research scale to measure challenging behav-
iours [37]. Instead, we used assessment items commonly 
mandated for use in clinical mental health services [38], 
Table 3  Multivariable model of antipsychotic use in children with ASD by socio-demographic characteristics and other covariates
OR odds ratio, CI confidence intervals
a aOR, adjusted Odds Ratio, fully adjusting for all other covariates within the table, i.e. socio-demographic (age at CAMHS assessment, gender 
and ethnicity) and parental and neighbourhood characteristics, challenging behaviours, adaptive function and co-existing ICD-10 mental and 
behavioural disorder groupings: hyperkinetic (F90), depressive disorders (F32), psychosis (F1x.5, F20–F29, F31, F32.3, F33.3) oppositional and 
conduct (F91–F92), anxiety, stress and emotional (F40–41, F43–F48, F93), obsessive–compulsive (OCD, F42), tic (F95), intellectual disability 
(ID, F70–F79) and other psychiatric diagnosis
OR (95 % CI) (n = 3482) P aOR (95 % CI)a P
Female sex (vs male) 1.39 (1.09–1.79) 0.009 1.02 (0.71–1.46) 0.89
 Age at CAMHS assessment 1.18 (1.15–1.23) <0.0001 1.11 (1.05–1.16) <0.001
Ethnicity
 White British Reference
 White other 0.49 (0.26–0.92) 0.026 0.62 (0.24–1.55) 0.31
 East Asian 1.08 (0.52–2.21) 0.83 0.91 (0.35–2.31) 0.84
 British/Black African 0.68 (0.50–0.92) 0.014 1.14 (0.73–1.78) 0.55
 British/Black Caribbean 0.28 (0.11–0.70) 0.006 0.56 (0.21–1.54) 0.26
 Mixed Heritage 0.75 (0.52–1.09) 0.13 0.78 (0.46–1.32) 0.36
 South Asian 1.06 (0.56–2.05) 0.84 1.26 (0.47–3.32) 0.70
 Not stated 0.24 (0.12–0.45) <0.001 0.27 (0.09–0.80) 0.02
Adaptive function
 Children’s Global Assessment Scale (CGAS) 0.95 (0.94–0.95) <0.0001 0.96 (0.95–0.97) <0.0001
Challenging behaviours
 Self-injury 4.80 (3.72–6.20) <0.0001 1.85 (1.30–2.63) <0.0001
 ID-related harm 1.63 (1.27–2.07) <0.0001 0.72 (0.49–1.06) 0.10
 Aggression 3.57 (2.77–4.59) <0.0001 2.14 (1.50–2.06) <0.0001
 Self-neglect 3.48 (2.61–4.67) <0.0001 1.20 (0.78–1.80) 0.35
 High-risk behaviours 3.40 (2.66–4.35) <0.0001 1.22 (0.86–1.73) 0.27
Family characteristics
 Caregiver mental illness 1.0 (0.75–1.31) 0.98 0.87 (0.60–1.26) 0.47
 Caregiver substance misuse 0.71 (0.42–1.20) 0.20 0.57 (0.30–1.08) 0.09
 High parental concern 4.05 (2.79–5.85) <0.0001 2.02 (1.27–3.22) 0.003
Neighbourhood
Level of deprivation (tertiles)
 1st (least deprived) Reference
 2nd 0.62 (0.47–0.81) 0.001 0.82 (0.56–1.19) 0.31
 3rd (most deprived) 0.54 (0.40–0.71) <0.0001 0.91 (0.62–1.35) 0.65
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which could likely aid study replication in other UK set-
tings. Fifth, we coded comorbid disorders preceding and 
up to 30 days post antipsychotic use, which prevented the 
exclusion of pre-medication diagnostic reports. Theoreti-
cally, this could introduce an observer bias, as the intensity 
of observation by the CAMHS service post antipsychotic 
treatment may increase a child’s risk of having a clinically 
recorded comorbid disorder. However, iatrogenic comor-
bid psychiatric conditions are very unlikely to develop or 
be recorded within this short timeframe. Last, due to limi-
tations in the free text coding and extraction process, we 
cannot exclude residual confounding as an influence on our 
findings, especially within the broad diagnostic categories 
of psychotic disorder or intellectual disability. We were 
unable to accurately categorise the degree of intellectual 
disability, nor characterise the severity or duration of psy-
chotic disorder from the electronic health records. How-
ever, we did address potential confounding due to severity 
of psychotic disorders and intellectual disability to some 
extent by the inclusion of Children’s Global Assessment 
Score [27] as a covariate in the final multivariable models. 
Residual confounding may remain nonetheless.
Our findings reflect the complexity of assessing and 
treating comorbid psychiatric disorders in ASD. For exam-
ple, ASD and psychotic disorders pose a common diag-
nostic challenge to clinicians given their overlapping char-
acteristics and high potential for co-occurrence [39, 40]. 
We found only 47 % of children with ASD and psychosis 
received antipsychotics. This low treatment rate may be 
due to diagnostic uncertainty. Children with ASD may be 
more likely to have their diagnosis of psychosis withdrawn 
after further clinical assessment, and before the initiation 
of antipsychotic treatment. A second reason may relate to 
clinicians, children and their families deciding that some 
psychotic symptoms in ASD do not warrant antipsychotic 
treatment. Evidence that may dissuade those from starting 
antipsychotic treatment includes findings from longitudi-
nal studies, which show fluctuating psychotic symptoms 
in children with features of autism can have a relatively 
benign course [41, 42].
Our findings provide a detailed account of current antip-
sychotic prescribing practices in a clinical population of 
children with ASD, which show that aggression and self-
injurious behaviours are significantly associated with antip-
sychotic use. Irritability may be an underlying treatment 
target driving the association between these behaviours and 
antipsychotic treatment. It may also underlie the associa-
tions we found between antipsychotic use and hyperkinetic, 
depressive and obsessive–compulsive disorders. Alterna-
tively, disorder specific symptoms may be targeted. For 
example, trial data have shown that risperidone and ari-
piprazole both significantly reduce hyperactivity and obses-
sional compulsive symptoms in ASD [37, 43]. In addition, 
the study findings highlight the need for further research in 
childhood ASD to determine which psychotic phenomena 
warrant antipsychotic treatment. This would help clinicians 
reduce the harms associated with both antipsychotic under-
use (i.e. prolonging the duration of untreated psychosis) 
and over-use. Future research might valuably include chil-
dren without ASD as comparison groups and employ more 
intricate text extraction methodologies to assess symp-
tom-specific severity and impairment. This would reduce 
the residual confounding effects that may occur when 
using broad diagnostic categories, and determine whether 
Table 4  Multivariable model 
of antipsychotic use in a cohort 
of children with ASD by 
psychiatric comorbidity
a aOR, adjusted Odds Ratio, adjusting for socio-demographic and parental and neighbourhood character-
istics, challenging behaviours, adaptive function and co-existing ICD-10 Mental and behavioural disorder 
groupings: hyperkinetic (F90), depressive disorders (F32), psychosis (F1x.5, F20–F29, F31, F32.3, F33.3), 
oppositional and conduct (F91–F92), anxiety, stress and emotional (F40–41, F43–F48, F93), obsessive–
compulsive (OCD, F42), tic (F95), intellectual disability (ID, F70–F79) and other psychiatric diagnosis
b Remaining, rarely occurring diagnoses, were collapsed into a single category labelled Other (includes 
ICD-10 F50 eating disorders, F04–09 organic disorders, F1x.1–4 substance misuse, F94.1–2 attachment 
disorders)
OR (95 % CI) (n = 3482) P aORa (95 % CI) P
Any comorbid disorder 4.27 (3.22–5.66) <0.0001 – –
Hyperkinetic 1.73 (1.36–2.18) <0.0001 1.44 (1.01–2.06) 0.042
Oppositional and conduct 2.47 (1.77–3.43) <0.0001 1.55 (0.96–2.51) 0.073
Depression 2.95 (1.99–4.36) <0.0001 2.36 (1.37–4.09) 0.002
Anxiety, emotional and stress 1.84 (1.31–2.59) <0.0001 1.20 (0.72–1.98) 0.484
Obsessive–compulsive 3.48 (2.19–5.53) <0.0001 2.31 (1.16–4.61) 0.017
Tic 3.16 (1.67–5.99) <0.0001 2.76 (1.09–6.95) 0.032
Psychosis 9.1 (6.19–13.4) <0.0001 5.71 (3.28–10.6) <0.0001
Intellectual disability 2.33 (1.82–2.97) <0.0001 1.68 (1.11–2.53) 0.015
Otherb 1.49 (0.89–2.48) 0.13 1.62 (0.83–3.16) 0.157
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comorbid psychiatric diagnoses in clinical practice are 
approached differently in children with ASD.
Our findings highlight a mismatch between current clini-
cal trials and the evidence needed to support clinical prac-
tice in ASD. Antipsychotic use was much greater in ado-
lescents and for those with comorbid diagnoses. However, 
most published trials exclude children with comorbidity 
and rarely recruit adolescents [7, 8, 11]. Importantly, we 
show social factors play a significant part in antipsychotic 
use. This provides an impetus to examine the association 
of antipsychotic treatment against contextual, as well as 
clinical factors. Controversy between the potential harm of 
both over- and under-use of antipsychotics in children with 
ASD continues, and underlies considerable public concern 
[15]. Large-scale cohort studies in real world settings, such 
as ours, eventually leading to pragmatic trials using elec-
tronic patient records, will help this debate become better 
informed.
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